HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

E Pearlman Selected Research

Ocular Onchocerciasis (River Blindness)

6/2012Differential induction of Th2- and Th1-associated responses by filarial antigens and endosymbiotic Wolbachia in a murine model of river blindness.
9/2007Filaria/Wolbachia activation of dendritic cells and development of Th1-associated responses is dependent on Toll-like receptor 2 in a mouse model of ocular onchocerciasis (river blindness).
6/2001Distinct roles for PECAM-1, ICAM-1, and VCAM-1 in recruitment of neutrophils and eosinophils to the cornea in ocular onchocerciasis (river blindness).
3/2001CXC chemokine receptor 2 but not C-C chemokine receptor 1 expression is essential for neutrophil recruitment to the cornea in helminth-mediated keratitis (river blindness).
11/2000Impaired eosinophil recruitment to the cornea in P-selectin-deficient mice in Onchocerca volvulus keratitis (River blindness).
7/2000Angiogenic activity of Onchocerca volvulus recombinant proteins similar to vespid venom antigen 5.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


E Pearlman Research Topics

Disease

6Ocular Onchocerciasis (River Blindness)
06/2012 - 07/2000
4Keratitis
03/2001 - 07/2000
3Infections
06/2012 - 06/2000
2Inflammation (Inflammations)
07/2001 - 11/2000
2Intestinal Volvulus (Volvulus)
12/2000 - 07/2000
2Eosinophilia
06/2000 - 01/2000
1Migraine Disorders (Migraine)
01/2020
1Filarial Elephantiasis (Lymphatic Filariasis)
09/2007
1Arthus Reaction
07/2001
1Corneal Diseases (Corneal Disease)
07/2001
1Pulmonary Eosinophilia (Eosinophilic Pneumonia)
03/2001
1Pneumonia (Pneumonitis)
03/2001
1Respiratory Hypersensitivity
03/2001
1Drug Resistant Epilepsy
02/2001
1Onchocerciasis
09/2000
1Corneal Neovascularization
07/2000
1Filariasis
06/2000

Drug/Important Bio-Agent (IBA)

3Interleukin-5 (Interleukin 5)IBA
06/2012 - 06/2000
3AntigensIBA
06/2012 - 12/2000
3CytokinesIBA
03/2001 - 01/2000
1Calcitonin Gene-Related PeptideIBA
01/2020
1galcanezumabIBA
01/2020
1Type A Botulinum Toxins (Botox)FDA Link
01/2020
1Monoclonal AntibodiesIBA
01/2020
1Toll-Like Receptor 2IBA
09/2007
1Complement System Proteins (Complement)IBA
07/2001
1Antigen-Antibody Complex (Immune Complex)IBA
07/2001
1ElementsIBA
07/2001
1IgG Receptors (Fc gamma RI)IBA
07/2001
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
06/2001
1Platelet Endothelial Cell Adhesion Molecule-1IBA
06/2001
1Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
06/2001
1CC ChemokinesIBA
03/2001
1CXCR ReceptorsIBA
03/2001
1Chemokine ReceptorsIBA
03/2001
1Interleukin-8B ReceptorsIBA
03/2001
1Interleukin-4 (Interleukin 4)IBA
03/2001
1Interferon-gamma (Interferon, gamma)IBA
03/2001
1Interleukin-12 (IL 12)IBA
03/2001
1P-SelectinIBA
11/2000
1E-SelectinIBA
11/2000
1Diethylcarbamazine (Hetrazan)FDA Link
09/2000
1SolutionsIBA
09/2000
1Proteins (Proteins, Gene)FDA Link
07/2000
1Messenger RNA (mRNA)IBA
01/2000

Therapy/Procedure

2Therapeutics
01/2020 - 02/2001
1Vagus Nerve Stimulation
02/2001
1Immunotherapy
11/2000